Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA P | $0.376 -2.56% 64K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
RNA | News M | $25.105 -0.14% -0.14% 560K
|
Health Technology
|
| O: 2.44%
H: 0.15%
C: -8.45%
disease positive key trial living
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.11%
H: 0.44%
C: -1.88%
abrysvo positive rsv
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Published: 2024-02-28 (Crawled : 19:00) - biospace.com/
VANI | $1.735 -3.61% -3.75% 51K
|
Manufacturing
|
| O: 499.01%
H: 28.93%
C: -38.18%
npm-115 ozempic obesity positive preclinical medical
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
ENSC | $0.5583 1.58% 43K
|
Health Technology
|
| O: 2.12%
H: 0.02%
C: -2.19%
nasdaq positive
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 4.56%
H: 4.17%
C: 2.22%
japan positive pharmaceuticals china results study
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Published: 2024-02-27 (Crawled : 12:00) - prnewswire.com
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 81.31%
H: 29.0%
C: 21.9%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 14.46%
H: 11.02%
C: 4.72%
vk2735 obesity agonist positive trial therapeutics results
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
PTCHF | $2.64 19.97% 870
|
n/a
|
| O: -0.56%
H: 0.0%
C: -0.38%
AKLI | $0.249 4.18% 4.02% 150K
|
|
| O: -3.85%
H: 12.67%
C: 6.92%
japan positive endeavorrx adhd trial results
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
AKLI | $0.249 4.18% 4.02% 150K
|
|
| O: 193.1%
H: 13.69%
C: -30.36%
endeavorrx japan positive adhd trial results
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MTNB | $0.1818 0.17% 0.0% 520K
|
Health Technology
|
| O: 1.59%
H: 15.13%
C: 10.61%
mat2203 positive update biopharma
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $42.45 -1.85% -1.88% 220K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Waldencast Receives Positive Nasdaq Listing Determination
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
WALD | $5.28 -1.49% -1.52% 39K
|
|
| O: 0.15%
H: 8.86%
C: 0.15%
nasdaq positive
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2024-02-24 (Crawled : 20:20) - globenewswire.com
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
| Email alert
Add to watchlist
urticaria positive week therapeutics results study
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | News | $45.205 -4.73% -4.97% 1.1M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-23 (Crawled : 12:30) - prnewswire.com
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 4.45%
H: 1.85%
C: -2.56%
tp53 astct positive leukemia trial therapy
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.25%
H: 2.95%
C: 2.88%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.05%
qalsody first chmp genetic positive treat therapy
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 3.69%
H: 1.07%
C: -2.58%
nephropathy chmp positive treatment therapeutics
Gray Finishes 2023 In A Strong Position and Issues Positive Outlook for 2024
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
GTN | $6.02 1.69% 0.0% 900K
|
Consumer Services
|
| O: -8.43%
H: 1.65%
C: -15.66%
positive
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Published: 2024-02-23 (Crawled : 07:00) - prnewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 3.69%
H: 1.07%
C: -2.58%
nephropathy chmp positive treatment therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.